Skip to content
Prostate Cancer Research Center

Faculty of Medicine and Health Technology

Molecular Biology of Prostate Cancer

2020

Search PubMed

2019

Search PubMed

2018

Search PubMed

2017

  1. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  2. Kivinummi, K, Urbanucci, A, Leinonen, K, Tammela, TLJ, Annala, M, Isaacs, WB et al.. The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Sci Rep. 2017;7 (1):17978. doi: 10.1038/s41598-017-18210-3. PubMed PMID:29269934 PubMed Central PMC5740165.
  3. Neupane, S, Steyerberg, E, Raitanen, J, Talala, K, Pylväläinen, J, Taari, K et al.. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. Int J Urol. 2018;25 (3):270-276. doi: 10.1111/iju.13508. PubMed PMID:29224236 .
  4. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  5. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. BMC Cancer. 2017;17 (1):585. doi: 10.1186/s12885-017-3579-8. PubMed PMID:28851310 PubMed Central PMC5575900.
  6. Saarimäki, L, Hugosson, J, Tammela, TL, Carlsson, S, Talala, K, Auvinen, A et al.. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. Eur Urol Focus. 2019;5 (2):186-191. doi: 10.1016/j.euf.2017.07.007. PubMed PMID:28803925 PubMed Central PMC5809235.
  7. Auvinen, A, Rannikko, A, Taari, K, Kujala, P, Mirtti, T, Kenttämies, A et al.. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32 (6):521-527. doi: 10.1007/s10654-017-0292-5. PubMed PMID:28762124 .
  8. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. Eur Urol Focus. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  9. Shore, ND, Tammela, TL, Massard, C, Bono, P, Aspegren, J, Mustonen, M et al.. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus. 2018;4 (4):547-553. doi: 10.1016/j.euf.2017.01.015. PubMed PMID:28753851 .
  10. Fizazi, K, Massard, C, Bono, P, Kataja, V, James, N, Tammela, TL et al.. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Eur Urol Focus. 2017;3 (6):606-614. doi: 10.1016/j.euf.2017.01.010. PubMed PMID:28753849 .
  11. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  12. Eskelinen, TJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Components of metabolic syndrome and prognosis of renal cell cancer. Scand J Urol. 2017;51 (6):435-441. doi: 10.1080/21681805.2017.1352616. PubMed PMID:28743221 .
  13. Tammela, TL, Häggman, M, Ladjevardi, S, Taari, K, Isotalo, T, Lennernäs, H et al.. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. J Urol. 2017;198 (6):1333-1339. doi: 10.1016/j.juro.2017.07.072. PubMed PMID:28736321 .
  14. Na, R, Helfand, BT, Chen, H, Conran, CA, Crawford, SE, Hayward, SW et al.. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate. 2017;77 (11):1213-1220. doi: 10.1002/pros.23380. PubMed PMID:28656603 PubMed Central PMC5565164.
  15. Lehto, US, Aromaa, A, Tammela, TL. Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. Eur J Cancer Care (Engl). 2018;27 (1):. doi: 10.1111/ecc.12729. PubMed PMID:28634991 .
  16. Urbanucci, A, Barfeld, SJ, Kytölä, V, Itkonen, HM, Coleman, IM, Vodák, D et al.. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017;19 (10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PubMed PMID:28591577 PubMed Central PMC5675034.
  17. Kallio, J, Hämäläinen, M, Luukkaala, T, Moilanen, E, Tammela, TL, Kellokumpu-Lehtinen, PL et al.. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. Urol Oncol. 2017;35 (9):544.e25-544.e31. doi: 10.1016/j.urolonc.2017.05.005. PubMed PMID:28572026 .
  18. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017;77 (9):1029-1035. doi: 10.1002/pros.23359. PubMed PMID:28480542 .
  19. Murtola, TJ, Virkku, A, Talala, K, Stenman, UH, Taari, K, Tammela, TLJ et al.. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. J Urol. 2017;198 (2):305-309. doi: 10.1016/j.juro.2017.02.069. PubMed PMID:28216328 .
  20. Kilpeläinen, TP, Pogodin-Hannolainen, D, Kemppainen, K, Talala, K, Raitanen, J, Taari, K et al.. Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. J Urol. 2017;198 (1):50-57. doi: 10.1016/j.juro.2017.01.048. PubMed PMID:28104375 .
  21. Haring, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51 (1):5-12. doi: 10.1080/21681805.2016.1271353. PubMed PMID:28084175 .
  22. Nevalainen, J, Stenman, UH, Tammela, TL, Roobol, M, Carlsson, S, Talala, K et al.. What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiol. 2017;46 :14-19. doi: 10.1016/j.canep.2016.11.005. PubMed PMID:27889661 PubMed Central PMC5415347.
  23. Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS et al.. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71 (2):151-154. doi: 10.1016/j.eururo.2016.07.032. PubMed PMID:27477525 PubMed Central PMC5570461.

Search PubMed

2016

Search PubMed

2015

Search PubMed